Segment Reporting and Foreign Operations (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Long-lived Assets by Geographic Area

Our long-lived assets (which are comprised of our net property and equipment) by geographic area at December 31, 2024, 2023 and 2022, consisted of the following (in thousands):

	2024		2023		2022
United States	$	271,734	$	273,105	$	281,290
Ireland		45,325		42,333		40,749
Other foreign countries		69,106		68,085		60,937
Total	$	386,165	$	383,523	$	382,976

Schedule of Segment Reporting Information, by Segment

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2024, 2023 and 2022, are as follows (in thousands):

	Year Ended						Year Ended						Year Ended
	December 31, 2024						December 31, 2023						December 31, 2022
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	1,301,744	$	54,770	$	1,356,514	$	1,220,560	$	36,806	$	1,257,366	$	1,118,224	$	32,757	$	1,150,981
Cost of sales standard(1)		549,657		15,746				534,826		12,987				496,678		12,739
Cost of sales other(2)		140,948		6,830				125,388		293				121,045		1,420
Selling, general and administrative expenses		376,734		22,997				362,082		11,594				332,012		10,513
Research and development expenses		83,812		3,654				80,300		2,428				74,042		1,468
Other operating expenses(3)		443		—				3,524		—				13,501		—
Income from operations	$	150,150	$	5,543	$	155,693	$	114,440	$	9,504	$	123,944	$	80,946	$	6,617	$	87,563
Total other expense — net						(5,700)						(11,855)						(4,934)
Income before income taxes					$	149,993					$	112,089					$	82,629

(1) Cost of sales standard represents costs of goods sold measured at the internal standard cost for production of inventory. Inventory standard costs include material, labor and manufacturing overhead.

(2) Cost of sales other for all segments include amortization expense associated with our developed technology and license agreement intangible assets, freight and handling associated with shipments to customers, provisions based on estimated excess, slow moving and obsolete inventories, manufacturing and price variances, and royalties.

(3) Other operating expenses include impairment charges, contingent consideration (benefit expense) related to the changes in fair value of contingent payments associated with acquisitions, acquired in-process research and development expense, and certain legal settlements.

	2024		2023		2022
Cardiovascular	$	97,749	$	88,960	$	80,777
Endoscopy		4,960		1,025		1,027
Total	$	102,709	$	89,985	$	81,804

Total depreciation and amortization by operating segment for the years ended December 31, 2024, 2023 and 2022, consisted of the following (in thousands):